TotalMarketCap

SAB Biotherapeutics

SABSNasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$266.590 M

$2.93 -7.86%

Close of 6 Nov 2026

As of 6 Nov 2026, SAB Biotherapeutics (SABS) has a market capitalization of $266.6M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$0.00

#3616 by revenue

Earnings

$13.3M

#1978 by earnings

Shares outstanding

90,088,831

Latest filing cover page

P/E ratio

20.1

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #87Precision BiosciencesDTIL$274.7M
  2. #88Century TherapeuticsIPSC$273.4M
  3. #89SAB BiotherapeuticsSABS$266.6M
  4. #90Lineage Cell TherapeuticsLCTX$247.3M
  5. #91Lexeo TherapeuticsLXEO$239.6M

What if SAB Biotherapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$310,341.81

Per share 105,919× higher

Bitcoin $1.53T

$16,792.05

Per share 5,731× higher

Apple $5.02T

$55,126.75

Per share 18,815× higher

Or at a round number

$500.0M$1.00B$2.00B$5.00B

Where these numbers come from

Share counts and financials for SAB Biotherapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.